Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

Juan Miguel Mosquera, Sven Perner, Elizabeth M. Genega, Martin Sanda, Matthias D. Hofer, Kirsten D. Mertz, Pamela L. Paris, Jeff Simko, Tarek A. Bismar, Gustavo Ayala, Rajal B. Shah, Massimo Loda, Mark A. Rubin

Research output: Contribution to journalArticle

163 Scopus citations

Abstract

Purpose: More than 1,300,000 prostate needle biopsies are done annually in the United States with up to 16% incidence of isolated high-grade prostatic intraepithelial neoplasia (HGPIN). HGPIN has low predictive value for identifying prostate cancer on subsequent needle biopsies in prostate-specific antigen - screened populations. In contemporary series, prostate cancer is detected in ∼ 20% of repeat biopsies following a diagnosis of HGPIN. Further, discrete histologic subtypes of HGPIN with clinical implication in management have not been characterized. The TMPRSS2-ERG gene fusion that has recently been described in prostate cancer has also been shown to occur in a subset of HGPIN. This may have significant clinical implications given that TMPRSS2-ERG fusion prostate cancer is associated with a more aggressive clinical course. Experimental Design: In this study, we assessed a series of HGPIN lesions and paired prostate cancer for the presence of TMPRSS2-ERG gene fusion. Results: Fusion-positive HGPIN was observed in 16% of the 143 number of lesions, and in all instances, the matching cancer shared the same fusion pattern. Sixty percent of TMPRSS2-ERG fusion prostate cancer had fusion-negative HGPIN. Conclusions: Given the more aggressive nature of TMPRSS2-ERG prostate cancer, the findings of this study raise the possibility that gene fusion-positive HGPIN lesions are harbingers of more aggressive disease. To date, pathologic, molecular, and clinical variables do not help stratify which men with HGPIN are at increased risk for a cancer diagnosis. Our results suggest that the detection of isolated TMPRSS2-ERG fusion HGPIN would improve the positive predictive value of finding TMPRSS2-ERG fusion prostate cancer in subsequent biopsies. copy; 2008 American Association for Cancer Research.

Original languageEnglish (US)
Pages (from-to)3380-3385
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number11
DOIs
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications'. Together they form a unique fingerprint.

  • Cite this

    Mosquera, J. M., Perner, S., Genega, E. M., Sanda, M., Hofer, M. D., Mertz, K. D., Paris, P. L., Simko, J., Bismar, T. A., Ayala, G., Shah, R. B., Loda, M., & Rubin, M. A. (2008). Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clinical Cancer Research, 14(11), 3380-3385. https://doi.org/10.1158/1078-0432.CCR-07-5194